You just read:

Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)

News provided by

Actelion Pharmaceuticals US, Inc.

Mar 15, 2019, 09:00 ET